ATE453404T1 - Dna-impfung zur behandlung von autoimmunerkrankungen - Google Patents

Dna-impfung zur behandlung von autoimmunerkrankungen

Info

Publication number
ATE453404T1
ATE453404T1 AT05015105T AT05015105T ATE453404T1 AT E453404 T1 ATE453404 T1 AT E453404T1 AT 05015105 T AT05015105 T AT 05015105T AT 05015105 T AT05015105 T AT 05015105T AT E453404 T1 ATE453404 T1 AT E453404T1
Authority
AT
Austria
Prior art keywords
autoimmune diseases
dna vaccination
treat autoimmune
vaccination
recipient
Prior art date
Application number
AT05015105T
Other languages
English (en)
Inventor
Lawrence Steinman
Pedro Jose Ruiz
Hideki Garren
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE453404T1 publication Critical patent/ATE453404T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05015105T 1999-03-12 2000-03-10 Dna-impfung zur behandlung von autoimmunerkrankungen ATE453404T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26759099A 1999-03-12 1999-03-12

Publications (1)

Publication Number Publication Date
ATE453404T1 true ATE453404T1 (de) 2010-01-15

Family

ID=23019424

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00912207T ATE308244T1 (de) 1999-03-12 2000-03-10 Dna-impfung zur behandlung von autoimmunerkrankungen
AT05015105T ATE453404T1 (de) 1999-03-12 2000-03-10 Dna-impfung zur behandlung von autoimmunerkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00912207T ATE308244T1 (de) 1999-03-12 2000-03-10 Dna-impfung zur behandlung von autoimmunerkrankungen

Country Status (9)

Country Link
EP (3) EP2177228A1 (de)
JP (1) JP2003508346A (de)
AT (2) ATE308244T1 (de)
CA (1) CA2363269C (de)
DE (2) DE60043624D1 (de)
DK (2) DK1621208T3 (de)
ES (2) ES2338890T3 (de)
PT (1) PT1621208E (de)
WO (1) WO2000053019A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162077A0 (en) * 2001-11-21 2005-11-20 Univ Leland Stanford Junior Polynucleotide therapy the board of trustees of the leland stanford junior university
CN101541954B (zh) 2006-11-30 2012-12-26 Medipost株式会社 含有人脐带血衍生的间充质干细胞的组合物诱导神经前体细胞或神经干细胞分化和增殖为神经细胞的用途
CN100571786C (zh) * 2007-03-26 2009-12-23 中国农业大学 一种预防和/或治疗自身免疫疾病的疫苗
KR20100054711A (ko) 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
SE535625C2 (sv) 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
KR101615161B1 (ko) 2011-02-02 2016-04-25 메디포스트(주) 신경질환의 예방 또는 치료를 위한 icam-1의 용도
GB201112806D0 (en) * 2011-07-26 2011-09-07 Bauer Johann Use of epitopes inducing specific tolerance for the prevention of tissue rejection
WO2013160865A1 (en) 2012-04-26 2013-10-31 Toleranzia Ab Immunotolerizing fusion proteins for treatment of multiple sclerosis
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US10898590B2 (en) 2015-09-21 2021-01-26 Kolon Life Science, Inc. Method for delivery of biological molecule to nervous tissue
KR20170034701A (ko) 2015-09-21 2017-03-29 코오롱생명과학 주식회사 통증 치료용 조성물
WO2023086969A2 (en) * 2021-11-12 2023-05-19 Ichor Medical Systems Inc. Treatment methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891435A (en) 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6274136B1 (en) * 1996-05-29 2001-08-14 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
AU3225097A (en) * 1996-06-03 1998-01-05 Auragen, Inc. Immunotherapy for autoimmune disease

Also Published As

Publication number Publication date
PT1621208E (pt) 2010-04-07
WO2000053019A1 (en) 2000-09-14
EP1621208A1 (de) 2006-02-01
ES2338890T3 (es) 2010-05-13
ES2251974T3 (es) 2006-05-16
EP1168923B1 (de) 2005-11-02
DE60043624D1 (de) 2010-02-11
ATE308244T1 (de) 2005-11-15
DE60023673T2 (de) 2006-07-20
EP1168923A1 (de) 2002-01-09
EP2177228A1 (de) 2010-04-21
EP1621208B1 (de) 2009-12-30
CA2363269C (en) 2012-06-12
JP2003508346A (ja) 2003-03-04
CA2363269A1 (en) 2000-09-14
DE60023673D1 (de) 2005-12-08
DK1621208T3 (da) 2010-05-10
DK1168923T3 (da) 2006-03-20
EP1168923A4 (de) 2002-06-26

Similar Documents

Publication Publication Date Title
ATE453404T1 (de) Dna-impfung zur behandlung von autoimmunerkrankungen
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
HK1078777A1 (en) Modified vaccinia virus ankara for the vaccination of neonates
FI932678A (fi) Pao alfavirus baserande dna expressionssystem
EP0445228A4 (en) Immunotherapy involving cd28 stimulation
ATE368378T1 (de) Dns-impfung zur einleitung einer suppressiven t- zell-antwort
ATE181501T1 (de) Verwendung von l-deprenyl zur hemmung des alterniedergangs des immunsystems in säugetieren
ATE486125T1 (de) Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren
AR026059A1 (es) Virus de plantas modificadas y metodos para su uso
Habibi et al. Cytokine gene expression in healing and non‐healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi‐quantitative RT–PCR
ATE71662T1 (de) Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung.
ATE226087T1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
ATE386543T1 (de) Verwendung polyklonaler anti-il-2 antikörper zur behandlung von insulin-abhängigen diabetes mellitus und lupus erythematosus
YU40796A (sh) Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije
DE60130775D1 (de) Stimulierung der neutrophilfunktion zur behandlung von entzündlichen darmerkrankungen
DE69528473T2 (de) Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen
PH23658A (en) Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor
ATE446767T1 (de) Gm-csf zur behandlung von morbus crohn
DE50005546D1 (de) Partikuläres konstrukt zur verwendung in der transplantationsmedizin
UA36324A (uk) Спосіб стимуляції гемопоетичної активності кріоконсервованого аломієлотрансплантата
LLOYD CELL TO CELL TRANSFER OF INTERFERON-INDUCED ANTIPROLIFERATIVE ACTIVITY IN VITRO AND ANTIVIRAL ACTIVITY IN VIVO.
ATE315082T1 (de) Myeloider koloniestimulierungsfaktor und verwendungen davon
Becker Homeostatic maintenance of memory CD8 T cells

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1621208

Country of ref document: EP